Algert Global LLC trimmed its position in ANI Pharmaceuticals Inc (NASDAQ:ANIP) by 9.1% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 27,295 shares of the specialty pharmaceutical company’s stock after selling 2,739 shares during the period. Algert Global LLC owned approximately 0.23% of ANI Pharmaceuticals worth $1,543,000 as of its most recent filing with the Securities & Exchange Commission.
Other institutional investors and hedge funds have also recently made changes to their positions in the company. Principal Financial Group Inc. raised its stake in ANI Pharmaceuticals by 2.4% during the first quarter. Principal Financial Group Inc. now owns 68,687 shares of the specialty pharmaceutical company’s stock worth $3,999,000 after acquiring an additional 1,630 shares in the last quarter. Piedmont Investment Advisors LLC acquired a new position in ANI Pharmaceuticals during the second quarter worth $140,000. Aperio Group LLC raised its stake in ANI Pharmaceuticals by 21.3% during the second quarter. Aperio Group LLC now owns 5,799 shares of the specialty pharmaceutical company’s stock worth $387,000 after acquiring an additional 1,019 shares in the last quarter. Crossmark Global Holdings Inc. acquired a new position in ANI Pharmaceuticals during the second quarter worth $235,000. Finally, Smith Asset Management Group LP raised its stake in ANI Pharmaceuticals by 15.8% during the second quarter. Smith Asset Management Group LP now owns 19,820 shares of the specialty pharmaceutical company’s stock worth $1,324,000 after acquiring an additional 2,710 shares in the last quarter. Institutional investors own 63.29% of the company’s stock.
ANIP has been the subject of several recent analyst reports. BidaskClub lowered ANI Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Wednesday, September 19th. ValuEngine lowered ANI Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday, October 8th. Cantor Fitzgerald set a $74.00 price objective on ANI Pharmaceuticals and gave the stock a “buy” rating in a research note on Wednesday, October 3rd. Finally, Canaccord Genuity set a $70.00 price objective on ANI Pharmaceuticals and gave the stock a “buy” rating in a research note on Friday, November 9th. Three research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. The company has an average rating of “Hold” and an average target price of $71.00.
ANI Pharmaceuticals stock opened at $53.50 on Friday. The company has a debt-to-equity ratio of 1.04, a current ratio of 3.34 and a quick ratio of 2.49. ANI Pharmaceuticals Inc has a 52-week low of $48.40 and a 52-week high of $73.49. The firm has a market cap of $626.47 million, a price-to-earnings ratio of 14.82 and a beta of 2.54.
ANI Pharmaceuticals (NASDAQ:ANIP) last released its quarterly earnings data on Tuesday, November 6th. The specialty pharmaceutical company reported $1.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.17 by $0.12. ANI Pharmaceuticals had a return on equity of 28.39% and a net margin of 0.23%. The firm had revenue of $50.70 million during the quarter, compared to analyst estimates of $50.97 million. During the same period in the prior year, the company posted $1.11 earnings per share. The business’s revenue for the quarter was up 5.3% compared to the same quarter last year. Equities analysts anticipate that ANI Pharmaceuticals Inc will post 4.54 EPS for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: “ANI Pharmaceuticals Inc (ANIP) Holdings Trimmed by Algert Global LLC” was originally reported by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this piece can be read at https://www.americanbankingnews.com/2018/12/08/ani-pharmaceuticals-inc-anip-holdings-trimmed-by-algert-global-llc.html.
About ANI Pharmaceuticals
ANI Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States. It focuses on producing controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations. The company offers Erythromycin Ethylsuccinate to treat infections; Esterified Estrogen with Methyltestosterone for treating vasomotor symptoms of menopause; Etodolac to treat pain caused by osteoarthritis, rheumatoid arthritis, and other conditions; Fenofibrate for treating hypercholesterolemia; Flecainide to treat arrhythmia; Fluvoxamine for treating obsessive-compulsive and social anxiety disorders; and hydrocortisone enema and cortenema to treat ulcerative colitis.
Featured Story: Day Trading – Risk Worth the Reward?
Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.